<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01567462</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00053735</org_study_id>
    <secondary_id>PK Button and Bladder Tumors</secondary_id>
    <nct_id>NCT01567462</nct_id>
  </id_info>
  <brief_title>PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors</brief_title>
  <acronym>PK Button</acronym>
  <official_title>PK Button Vaporization Electrode for Treatment of Bladder Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Olympus</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the use of two types of equipment during
      transurethral resection of bladder tumors (TURBT). The two types of surgical devices are: the
      monopolar loop electrocautery and the PlasmaKinetic (PK) Button Vaporization Electrode. These
      two devices do the same task but differ in the way they create electric current when removing
      cancerous tissue. The investigators hope to examine and compare the uses of these two
      surgical devices to see if any advantages do exist or whether they actually are similar. The
      goal of the study is to prove similarity in outcomes between the two techniques and analyze
      the outcomes resulting from each case.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will study the medical intervention used when bladder cancer patients present with
      a new or recurrent bladder tumor. Currently when patients report these tumors, they undergo a
      standard practice called transurethral resection of the bladder tumor (TURBT) in order to
      determine the stage of the cancer. This intervention, accomplished by looking through the
      urethra using an endoscope, is both diagnostic and potentially therapeutic. An adequately
      performed TURBT will provide the pathologist with enough tissue to provide tumor grade and
      stage information. Currently, TURBT is done using equipment called monopolar electrocautery
      which is in the form a 90-degree loop electrode. Although usually safe and sufficient, this
      technique can create technical challenges because it can be difficult to position the loop
      electrode in a dynamically changing cylindrical space (the bladder). Specifically, especially
      with larger bladder tumors, intraoperative bleeding can obscure visualization and result in
      incomplete tumor resection as well as inadequate sampling of the layers of the bladder needed
      to establish tumor stage. Furthermore, monopolar current can result in stimulation of a nerve
      (the obturator nerve) during resection of wall tumors, resulting in violent movement of the
      leg which can cause a potential bladder tear as well as possible (iliac) vessel injury.

      Conversely, a technique using bipolar energy, which has been available for many years, has
      been readily adopted for the surgical treatment of benign prostatic enlargement. The
      advantages of a bipolar electrical current include the direct return of electrical current to
      the loop rather than to a grounding pad placed on the patient's skin. This has the
      theoretical value of limiting the diffusion of electrical current, and therefore heat, to the
      surrounding tissue. A further refinement on bipolar energy has been the recent introduction
      of a piece of equipment called the PlasmaKinetic (PK) Button Vaporization electrode, which is
      currently approved by the Food and Drug Administration (FDA) for this indication. Coupling
      bipolar energy into the Button electrode would not only harness the benefits of less thermal
      spread but also would obviate the geometric challenges associated with loop electrodes during
      resection of bladder tumors. Procedural advantages would potentially include minimal
      bleeding, good visualization, and a reduction in the occurrence of the obturator reflex and
      concomitant bladder perforation.

      This study is a randomized double-arm trial examining the results of both techniques for
      bladder cancer TURBT procedures with a minimum of 120 patients at Emory. The purpose of this
      study is to measure the procedural (intraoperative), short term, as clinically indicated (4-6
      weeks), and long-term (3 months) outcomes of TURBT using the PK Button when compared to
      traditional monopolar loop electrocautery. The goal of the study is to prove equivalence in
      outcomes between the two techniques.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2012</start_date>
  <completion_date type="Actual">March 28, 2017</completion_date>
  <primary_completion_date type="Actual">March 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Procedural Complications</measure>
    <time_frame>Post-Intervention (Up to 30 Days)</time_frame>
    <description>The number of procedural complications describes the total number of post-operative bleeding, need for blood transfusion, bladder perforation, obturator nerve stimulation, catheterization time, or need for hospitalization or bladder irrigation events that occur within thirty days of the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Operative Time</measure>
    <time_frame>After Surgery Completion, Up to 174 Minutes</time_frame>
    <description>The average operative time was measured through study completion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Catheterization Time</measure>
    <time_frame>After Surgery Completion, Up to 336 Hours</time_frame>
    <description>The average duration of the catheterization time was measured through study completion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Disease Recurrence</measure>
    <time_frame>Post-Intervention (Up to 4 Months)</time_frame>
    <description>The number of participants who had disease recurrence within the four month follow up period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Monopolar Electrocautery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The current treatment standard of care for patients who present de novo or with a recurrent bladder tumor is transurethral resection of the bladder tumor (TURBT) using monopolar electrocautery in the form a 90-degree loop electrode and has been used since its introduction in 1952. This intervention, accomplished endoscopically through the urethra, is both diagnostic and potentially therapeutic. An adequately performed TURBT will provide the pathologist with enough tissue to provide tumor grade and stage information.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PK Button Vaporization Electrode</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bipolar energy has been available for many years and has been readily adopted for the surgical treatment of benign prostatic enlargement and may provide advantages and solutions to the technical challenges of monopolar electrocautery. A further refinement on bipolar energy has been the recent introduction of the PlasmaKinetic (PK) Button Vaporization electrode which will be used in the intervention arm of this study. This electrode is already approved by the Food and Drug Administration (FDA) for this indication as well. The semi-spherical design of the electrode creates a plasma arc that glides over the tissue, transmitting energy to the cell layers adjacent to the arc which are then quickly vaporized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Monopolar electrocautery loop in Transurethral resection of bladder tumors</intervention_name>
    <description>Standard monopolar electrocautery loop in transurethral resection of bladder tumors (TURBT)</description>
    <arm_group_label>Monopolar Electrocautery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PK Button Vaporization Electrode in transurethral resection of bladder tumors</intervention_name>
    <description>PlasmaKinetic (PK) Button Vaporization Electrode in transurethral resection of bladder tumors (TURBT)</description>
    <arm_group_label>PK Button Vaporization Electrode</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cystoscopically detected bladder tumors requiring TURBT

          -  Patients with bladder tumors which are endoscopically resectable by surgeon's judgment
             with only one trip into the operating room.

        Exclusion Criteria:

          -  Patients with clinical evidence of locally advanced, nodal, or metastatic bladder
             cancer

          -  Patients with hydronephrosis secondary to bladder cancer

          -  Patients with diffuse tumor throughout bladder that is deemed unresectable by surgeon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Ogan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Department of Urology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2012</study_first_posted>
  <results_first_submitted>September 14, 2017</results_first_submitted>
  <results_first_submitted_qc>November 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 8, 2017</results_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Kenneth Ogan, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>transurethral resection of bladder tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited between September 2012 and March 2017. Of the 95 participants who signed consent, 90 subjects began study participation.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Monopolar Loop Electrocautery</title>
          <description>Participants underwent a transurethral resection of the bladder tumor (TURBT) using monopolar loop electrocautery.</description>
        </group>
        <group group_id="P2">
          <title>PK Button Vaporization Electrode</title>
          <description>Participants underwent a transurethral resection of a bladder tumor using a PK button vaporization electrode.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who completed all study procedures per protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Monopolar Loop Electrocautery</title>
          <description>Participants completed a transurethral resection of the bladder tumor (TURBT) using monopolar loop electrocautery and all follow up procedures.</description>
        </group>
        <group group_id="B2">
          <title>PK Button Vaporization Electrode</title>
          <description>Participants completed a transurethral resection of a bladder tumor using a PK button vaporization electrode and all follow up procedures.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.7" spread="12.2"/>
                    <measurement group_id="B2" value="69.2" spread="11.4"/>
                    <measurement group_id="B3" value="69" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unreported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Procedural Complications</title>
        <description>The number of procedural complications describes the total number of post-operative bleeding, need for blood transfusion, bladder perforation, obturator nerve stimulation, catheterization time, or need for hospitalization or bladder irrigation events that occur within thirty days of the procedure.</description>
        <time_frame>Post-Intervention (Up to 30 Days)</time_frame>
        <population>Participants who completed all study procedures per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Monopolar Loop Electrocautery</title>
            <description>Participants underwent a transurethral resection of the bladder tumor (TURBT) using monopolar loop electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>PK Button Vaporization Electrode</title>
            <description>Participants underwent a transurethral resection of a bladder tumor using a PK button vaporization electrode.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Procedural Complications</title>
          <description>The number of procedural complications describes the total number of post-operative bleeding, need for blood transfusion, bladder perforation, obturator nerve stimulation, catheterization time, or need for hospitalization or bladder irrigation events that occur within thirty days of the procedure.</description>
          <population>Participants who completed all study procedures per protocol.</population>
          <units>complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Operative Time</title>
        <description>The average operative time was measured through study completion.</description>
        <time_frame>After Surgery Completion, Up to 174 Minutes</time_frame>
        <population>Participants who completed all study procedures per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Monopolar Loop Electrocautery</title>
            <description>Participants underwent a transurethral resection of the bladder tumor (TURBT) using monopolar loop electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>PK Button Vaporization Electrode</title>
            <description>Participants underwent a transurethral resection of a bladder tumor using a PK button vaporization electrode.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Operative Time</title>
          <description>The average operative time was measured through study completion.</description>
          <population>Participants who completed all study procedures per protocol.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" spread="28.7"/>
                    <measurement group_id="O2" value="56.4" spread="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Catheterization Time</title>
        <description>The average duration of the catheterization time was measured through study completion.</description>
        <time_frame>After Surgery Completion, Up to 336 Hours</time_frame>
        <population>Participants who required catheterization after the operative procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Monopolar Loop Electrocautery</title>
            <description>Participants underwent a transurethral resection of the bladder tumor (TURBT) using monopolar loop electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>PK Button Vaporization Electrode</title>
            <description>Participants underwent a transurethral resection of a bladder tumor using a PK button vaporization electrode.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Catheterization Time</title>
          <description>The average duration of the catheterization time was measured through study completion.</description>
          <population>Participants who required catheterization after the operative procedure.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" spread="74.9"/>
                    <measurement group_id="O2" value="45.9" spread="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Disease Recurrence</title>
        <description>The number of participants who had disease recurrence within the four month follow up period.</description>
        <time_frame>Post-Intervention (Up to 4 Months)</time_frame>
        <population>Participants who completed all study procedures per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Monopolar Loop Electrocautery</title>
            <description>Participants underwent a transurethral resection of the bladder tumor (TURBT) using monopolar loop electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>PK Button Vaporization Electrode</title>
            <description>Participants underwent a transurethral resection of a bladder tumor using a PK button vaporization electrode.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Disease Recurrence</title>
          <description>The number of participants who had disease recurrence within the four month follow up period.</description>
          <population>Participants who completed all study procedures per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the duration of the study (5 years).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Monopolar Loop Electrocautery</title>
          <description>Participants underwent a transurethral resection of the bladder tumor (TURBT) using monopolar loop electrocautery.</description>
        </group>
        <group group_id="E2">
          <title>PK Button Vaporization Electrode</title>
          <description>Participants underwent a transurethral resection of a bladder tumor using a PK button vaporization electrode.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative Bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Perforation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Continuous Bladder Irrigation</sub_title>
                <description>Need for continuous bladder irrigation.</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kenneth Ogan</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-3038</phone>
      <email>kogan@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

